API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Theophylline generic extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Lead Product(s): Theophylline
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Theo-Dur-Generic
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Details:
Cyrano intends to use the proceeds to advance FLAVOR, its Phase 2, double-blind, randomized clinical trial of CYR-064, an intranasal theophylline spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection.
Lead Product(s): Theophylline
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CYR-064
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: DeepWork Capital
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024